Topics in Palliative Medicine
Questions? Comments? Send us a message! [https://www.buzzsprout.com/twilio/text_messages/2436798/open_sms] We discuss a Phase 2a clinical trial investigating the use of intravenous DMT (SPL026) as a fast-acting treatment for major depressive disorder. The research demonstrates that a single dose, paired with psychotherapeutic support, leads to a rapid and significant reduction in symptoms that can last up to three months. Unlike traditional antidepressants that take weeks to work, this short-acting psychedelic provides an immediate effect and was found to be generally safe and well-tolerated by participants. Dr. Steve’s commentary emphasizes that this modern research addresses a forty-year gap in psychedelic studies caused by previous political and regulatory restrictions. Overall, the findings suggest that DMT could offer a highly efficient alternative for patients who do not respond well to conventional therapies. Check out simplyherbals.net [https://simplyherbals.net] and tell them Topics in Palliative Medicine sent you! Support the show [https://www.buzzsprout.com/2436798/support] Thank you for your interest in Ethics in Palliative Medicine! Follow us at https://epionepalliative.com and on X: @PallCareEthics
29 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de Topics in Palliative Medicine!